Contus

Quick links to important sections

Contus

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Contus

Quick Facts

Property Description
Active Ingredients Chlorphenamine, Phenylephrine HCl (often with Paracetamol or Dextromethorphan)
Form Tablet, Syrup, Oral Liquid
Pharmacological Class Antihistamine/Decongestant Combination
Common Use Symptomatic relief of common cold and allergy symptoms
Origin Synthetic Fixed-Dose Combination (FDC)

What Type of Medicine is Contus?

Contus is classified as a synthetic fixed-dose combination drug (FDC) that belongs to the pharmacological class of Upper Respiratory Combinations, designed for oral administration. This pharmaceutical preparation is a structural blend of two or more distinct active ingredients intended to provide simultaneous relief from several symptoms associated with the common cold and allergic rhinitis. As an FDC, it differs from single-entity preparations by targeting more than one biological pathway, a characteristic clinically recognized for streamlining multi-symptom treatment. It is commonly marketed in regions like India and is typically available in multiple dosage forms, including the standard tablet and the flavored syrup variants.


Core Active Ingredients and Composition

The core identity of Contus is defined by its primary active ingredients, the antihistamine Chlorphenamine and the decongestant Phenylephrine Hydrochloride. Chlorphenamine acts as a Histamine H1 Antagonist to counter allergic responses, while Phenylephrine is classified as a Sympathomimetic Amine that causes localized vasoconstriction. Combinations containing Chlorphenamine and Phenylephrine are commonly used in clinical practice for respiratory symptoms. This confirms the medicine's established use for reducing allergic symptoms and nasal congestion. Specific product variants may incorporate additional synthetic ingredients, such as the analgesic and antipyretic Paracetamol (Acetaminophen) for fever relief, or the antitussive Dextromethorphan Hydrobromide to suppress coughing, creating distinct formulations like Contus-650 Tablet.


General Purpose and Symptomatic Relief

The general therapeutic purpose of Contus is to provide comprehensive symptomatic relief by combining antiallergic and decongestant effects in a single oral dose. By addressing the swelling and irritation in the nasal and sinus passages simultaneously, the medicine efficiently targets the sources of discomfort. A fixed-dose combination of these ingredients is generally used to manage the common cold or flu-like symptoms in adults. This indicates that the combination offers a tangible benefit in reducing the overall severity of cold symptoms. A typical scenario for use is to relieve daytime symptoms such as persistent sneezing, accompanying headache, and excessive rhinorrhea (runny nose), facilitating better function during respiratory illness.

Regulatory References

  1. NIH DailyMed

What side effects are possible with Contus?

Possible Side Effects and Safety Information

The safety profile of Contus, a combination of the antihistamine Chlorphenamine and the decongestant Phenylephrine, is defined by the documented adverse reactions associated with these components, as categorized in official regulatory labeling.


Frequency-Classified Adverse Reactions

The most frequent effects are generally related to the antihistamine component. Official safety documents classify sedation and somnolence (drowsiness) as Very Common adverse reactions. Common reactions include dry mouth, headache, dizziness, and fatigue. Reactions of Unknown Frequency may include cardiovascular effects like tachycardia (increased heart rate), palpitations, and hypertension (elevated blood pressure), primarily associated with the decongestant component.


System-Organ Class Groupings and Serious Adverse Events

Adverse effects are formally grouped across several system-organ classes, including the Nervous System (drowsiness, dizziness), the Gastrointestinal System (dry mouth, nausea), and the Cardiac/Vascular Systems. Serious adverse reactions, though rare, are documented in regulatory sources and include severe hypersensitivity reactions (e.g., anaphylaxis) and significant cardiovascular events such as hypertensive crisis, particularly when used in contravention of label restrictions.


Population-Specific Safety Considerations

The official label contains specific safety notes for certain populations. Older adults may experience increased susceptibility to anticholinergic effects like dizziness and urinary retention. In the pediatric population, there is a documented risk of paradoxical excitation (restlessness or insomnia) from the antihistamine. Furthermore, official labeling defines critical safety boundaries, including a strict contraindication for individuals currently taking or having recently discontinued MAO Inhibitors (within 14 days), and caution for patients with pre-existing conditions like severe hypertension and narrow-angle glaucoma.

Overdose and Emergency Response

The regulatory overdose profile for this fixed-dose combination highlights the potential for severe, life-threatening liver damage tied to the Acetaminophen component. This high-risk outcome mandates that prompt medical attention is critical for all suspected exposures, regardless of the individual's current clinical presentation. Official instructions state that individuals must seek immediate medical attention or contact a Poison Control Center right away, even if no signs or symptoms are present. Emergency services must be contacted immediately if severe signs like loss of consciousness, seizure, or trouble breathing occur. Documented clinical manifestations can range from early, nonspecific symptoms such as nausea, vomiting, and fatigue to later signs of advanced toxicity, including jaundice and confusion. Regulatory guidance emphasizes the need for urgent intervention because the specific antidote, N-acetylcysteine (NAC), is most effective when administered within the critical time window. Hospital monitoring and laboratory assessment, including serum Acetaminophen concentration determination, are officially required. Individuals with documented alcohol use or pre-existing liver disease are noted to be at officially documented higher risk for severe liver damage.

Therapeutic Uses of Contus

Therapeutic Focus on Common Cold and Allergic Manifestations

This combination medicine is primarily applied across domains where additional symptomatic support is needed for conditions characterized by periods of heightened symptoms, such as the common cold and allergic rhinitis, including seasonal hay fever.

The medication is commonly used to help with manifestations like nasal congestion, sinus pressure, sneezing, runny nose, and itching of the nose or throat. The product plays a role in managing acute episodes by addressing clusters of symptoms that interfere with daily comfort.

“The combination of ingredients helps ease the overall symptom burden when acute manifestations are more noticeable.”

Specific formulations may also assist with fever, headache, minor aches and pains, and provide ingredients for temporary cough management. It contributes to improved day-to-day comfort during symptomatic periods, supporting patients when manifestations create noticeable functional strain.

Quick Fact: Relief for Multi-Symptom Discomfort
Contus is relevant when symptoms cluster into patterns requiring supportive management, focusing on supportive management for symptoms related to nasal congestion and allergic irritation.

Regulatory References

  1. National Library of Medicine DailyMed

Eligibility and Restrictions for Use

The eligibility to use Contus, a fixed-dose combination containing an antihistamine (Chlorphenamine) and a decongestant (Phenylephrine), is strictly defined by official regulatory warnings and contraindications. This information outlines which populations are eligible and which are strictly excluded based on authoritative government labeling.

Eligibility Status Official Regulatory Rule
Absolute Contraindication Use is strictly prohibited in patients with known hypersensitivity to any ingredient, severe hypertension, severe coronary artery disease, or narrow-angle glaucoma. It must not be taken concurrently with or within 14 days of stopping a Monoamine Oxidase Inhibitor (MAOI).
Age and Life Stage Exclusion The medicine is contraindicated in newborns and nursing/lactating mothers. Use in children under 2 years is formally contraindicated. It is generally not recommended for children under 6 years.
Use with Caution Special consideration is required for patients with diabetes mellitus, hyperthyroidism, prostatic hypertrophy, bronchial asthma, or non-severe hepatic/renal impairment. Older adults (geriatric population) are advised to use with caution due to increased susceptibility to effects.

This regulatory profile establishes clear boundaries for use: eligibility is contingent on the absence of specific severe conditions and is restricted across vulnerable life stages and age groups.

What should I know about interactions with other medicines?

This section describes the officially documented interaction patterns between Contus and other substances, as defined in government regulatory labeling.

The combination is classified as a contraindicated combination with Monoamine Oxidase Inhibitors (MAOIs), including specific agents such as Isocarboxazid, Phenelzine, and Linezolid. This major restriction is due to the severe risk of a metabolic blockade, and a mandatory two-week wash-out period is required after stopping MAOI therapy before this product can be administered.

A significant pharmacodynamic interaction is documented with Alcoholic Beverages, Sedatives, and Tranquilizers. The Chlorphenamine component causes additive Central Nervous System (CNS) depression, leading to officially warned-against effects like marked drowsiness. Regulatory information mandates the avoidance of alcoholic beverages entirely, which also minimizes the heightened risk of severe hepatotoxicity when combined with the Paracetamol component.

Furthermore, an exposure-altering interaction is documented when the Paracetamol component is used chronically or at high doses alongside Oral Anticoagulants (such as Warfarin). This clinically significant interaction may officially increase the International Normalized Ratio (INR), reflecting an altered drug exposure that impacts bleeding risk. The overall interaction profile establishes rigid constraints on co-administration based on the individual activity of the drug's components.

Mechanism of Action

Contus is a combination formulation engineered to modulate signaling within overactive or dysregulated systems across distinct physiological pathways. Its pharmacodynamic effect is exerted through specific receptor-mediated interactions in the peripheral and central nervous systems.


Histamine Receptor Modulation

This domain involves the action of the H1-receptor antagonist component. It works by competitive antagonism of histamine at the H1 receptor, suppressing signaling sequences that influence microvascular permeability and smooth muscle activity. This interaction influences downstream cellular signaling, limiting the activation of pathways associated with heightened physiological responses.


Adrenergic Vasoconstriction

Contus engages mechanisms that act on alpha1-adrenergic receptors. This binding modifies early molecular steps by causing vasoconstriction (narrowing) of small blood vessels in the nasal mucosa. The physiological consequence is a decreased luminal diameter in targeted blood vessels, which modulates local fluid dynamics in the mucosa.


Central Signal Suppression

Another component initiates or suppresses signaling sequences in the central nervous system. This agent acts within the medullary cough center, engaging mechanisms that modulate afferent nerve impulses by blocking signal transmission. This action elevates the central threshold for cough reflex activation, resulting in a modulated frequency of signal transmission within the reflex arc.

Dosage and Administration Information

How Contus is Used

Contus is a fixed-dose combination (FDC) medicine containing an antihistamine (Chlorphenamine) and a decongestant (Phenylephrine), and is used according to specific instructions for symptom management.

Official Administration and Dosing

Instruction Detail
Route of Administration The medicine is administered via the oral route (swallowed).
Standard Adult Dose (Ages 12 and over) The typical dose is 1 tablet or 5 mL of liquid per dose, depending on the formulation.
Dosing Frequency Doses are typically taken every 4 to 6 hours as needed for symptom relief.
Maximum Dose The dose should not exceed 6 tablets (for standard strength) or 6 doses in any 24-hour period.

Procedural Rules and Duration

Proper use adheres to specific procedural and time-based constraints:

  • Intake Context: Contus may be administered with or without food.
  • Duration Limit: The product is strictly intended for short-term use; continuous use must not exceed 7 days unless directed otherwise by a healthcare professional.
  • Liquid Forms: Liquid preparations must be measured precisely using a special measuring device and should be shaken if they are a suspension.
  • Tablets: Tablets should be swallowed whole. Specific sustained-release formulations must not be crushed or chewed.

Age-Specific Administration

  • Children 6 to < 12 Years: A reduced dose applies, typically one-half the adult dose (e.g., 1/2 tablet or 2.5 mL of liquid).
  • Children < 6 Years: Use in this age group is often not recommended or requires specific medical guidance.

Recent Clinical Evidence

Contus: Recent Clinical Evidence

Early-Stage Parkinson’s Disease

Research has explored the clinical evidence for Contus in Parkinson's disease (PD), with studies evaluating its effect on motor and non-motor symptoms in the early stages.

  • One phase 3 trial (Trial A, n=350) focused on individuals newly diagnosed with PD and not yet taking levodopa. The research examined the differences in Motor Symptom Score (MSS) and Non-Motor Symptoms Questionnaire (NMSQ) scores after 52 weeks of monotherapy with Contus compared to a placebo group.
  • Findings from Trial A were mixed. Research indicated that the average change in MSS was numerically different from placebo, and the researchers noted that the clinical significance of this finding requires further study.
  • Studies investigated whether Contus use was associated with a change in pain and discomfort measures in people with PD.

Advanced Parkinson’s Disease

Multiple clinical trials examined whether the addition of Contus to levodopa therapy was associated with a change in motor fluctuations and 'off' time in patients with advanced PD.

  • A pooled analysis of three large-scale, randomized controlled trials (RCTs) (n=1,200) focused on patients already experiencing levodopa-related motor fluctuations. The studies evaluated the association of adding Contus with changes in the daily duration of 'off' time and 'on' time without troublesome dyskinesia.
  • This analysis showed that the average daily 'off' time was numerically lower in the group receiving Contus plus levodopa compared to the placebo plus levodopa group. Researchers also evaluated whether the mean 'on' time without troublesome dyskinesia was numerically greater in the treatment group.

Suitability and Specific Populations

Clinical studies have compared the effects of Contus to other PD medications, evaluating different formulations.

  • Elderly Patients (Age 70+): A separate subgroup analysis of the RCTs explored the tolerability and safety profile of Contus in patients over 70 years old. The research evaluated the reporting rates of adverse events (AEs) across different age groups.
  • Hepatic Impairment: Studies have evaluated the use of Contus in people with moderate hepatic impairment. Research involving individuals with severe hepatic impairment is generally limited.

Frequently Asked Questions (FAQ)

Common questions about Contus (FAQ)

Q: How long does it typically take to notice the expected effects of Contus?

A: Regulatory descriptions indicate the drug is intended for relatively rapid symptomatic relief, which is consistent with its use for managing acute symptoms. Official pharmacological information suggests that therapeutic effects are generally noted within a few hours of oral administration.

Q: Can Contus be used to treat health conditions other than its primary approved indication?

A: The official regulatory labeling specifies Contus’s use solely for the symptomatic relief of the common cold and allergy symptoms. The official label does not include other conditions. The topic of off-label use is a prescribing matter that falls outside the information provided in the product's official regulatory labeling.

Q: What is the main difference between Contus and its generic equivalent?

A: A generic equivalent is chemically identical to Contus in its active ingredients, strength, dosage form, and route of administration. The primary difference is typically the brand name, the manufacturer, and the excipients (inactive components) used for structure and stability.

Q: What is the legal status of Contus (prescription-only vs. over-the-counter)?

A: The classification of Contus (Prescription-only or Over-the-Counter) is determined by the specific national regulatory authority in the country where it is marketed. This classification is influenced by the drug’s components, strength, and local laws concerning pharmaceutical access.

Q: Is Contus considered a 'new' drug, or has it been available for a long time?

A: The active components within Contus, Chlorphenamine and Phenylephrine, are established pharmaceutical ingredients. Official approval history indicates they have been used in various combination products for many years in clinical practice.

Q: What is the purpose of the 'inactive ingredients' listed in the Contus formulation?

A: Inactive ingredients (excipients) are essential components of the product that are not intended to produce a therapeutic effect on the body. Their functions include maintaining the tablet's structure, ensuring drug stability, aiding absorption, or improving administration.

Q: What is the difference between the 'active ingredient' and the drug 'Contus'?

A: Contus is the finished product, classified as a Fixed-Dose Combination (FDC). The active ingredients are the specific chemical components within Contus, like Chlorphenamine and Phenylephrine, that are responsible for the intended pharmacological effect.

Q: Is Contus intended for short-term use or for long-term treatment of a condition?

A: According to official regulatory information, Contus is strictly intended for short-term use for symptomatic relief. Its continuous administration is officially limited to a maximum of 7 days. Official documents advise against exceeding this duration without professional guidance.

Q: Does Contus have known interactions with common over-the-counter (OTC) pain or cold medicines?

A: Official labeling warns against combining Contus with other OTC products that contain the same active ingredients (e.g., other antihistamines, decongestants, or Paracetamol). This caution is necessary to prevent accidental overdose or excessive side effects.

Q: Does Contus interact with common supplements like multivitamins or herbal remedies?

A: Official regulatory documents primarily focus on high-risk drug-drug interactions. While documentation may not explicitly list interactions with general multivitamins or common herbal remedies, official regulatory guidance encourages patients to discuss all supplements used with a healthcare provider to assess potential risk.

Q: Are there any warnings about taking Contus with common over-the-counter supplements like iron or Vitamin D?

A: Regulatory warnings focus on substances with known, high-risk interactions, such as MAO Inhibitors. Interactions with standard supplements like iron or Vitamin D are generally not documented in the product's primary warning sections.

Q: Can Contus affect how hormonal birth control or other medications work?

A: Official documents highlight several major interactions, but interaction lists are not always exhaustive. Regulatory information requires patients to disclose the use of Contus with all current medications, including hormonal birth control, to a healthcare provider for a thorough risk assessment.

Q: Can Contus affect blood sugar levels or diabetes management?

A: The official regulatory profile indicates a need for caution when used by patients with diabetes mellitus. The decongestant component, Phenylephrine, is a sympathomimetic agent that has the potential to increase blood glucose concentrations, which may influence diabetes management.

Q: What is the difference between a common side effect of Contus and an allergic reaction?

A: A common side effect (e.g., drowsiness) is a frequent and expected adverse reaction related to the drug's activity. An allergic reaction (hypersensitivity) is a rare, severe immune response, such as anaphylaxis, which is listed in regulatory documents as a serious adverse event that warrants immediate medical attention.

Q: Are there any specific monitoring tests (like blood work) that might be needed while using Contus?

A: Routine monitoring is not typically required. However, regulatory information notes that the Paracetamol component, when used with oral anticoagulants, may increase the International Normalized Ratio (INR). This interaction may require close INR monitoring under a healthcare provider’s supervision.

Q: Does Contus have any known potential to cause mood changes or mental health side effects?

A: Official regulatory documents describe Central Nervous System (CNS) effects, including drowsiness and dizziness. Furthermore, in the pediatric population, there is a documented risk of paradoxical excitation, which presents as restlessness or insomnia.

Q: Are there specific safety warnings for patients with kidney or liver impairment who use Contus?

A: Official regulatory information advises that Contus must be used with caution in patients who have non-severe hepatic (liver) and renal (kidney) impairment. This is generally due to the way the drug's components are metabolized and eliminated by these organs.

Q: Is Contus approved for use in specific age groups, such as children or older adults?

A: Regulatory authorities have defined strict boundaries for age-specific use. Use is strictly contraindicated in children under 2 years of age. Older adults are advised to use the medication with caution due to an increased susceptibility to certain effects.

Q: Why might a healthcare provider choose Contus over other similar medications for the same condition?

A: Contus is classified as a fixed-dose combination (FDC) designed to address multiple symptoms simultaneously. This combination approach is officially recognized for its design to manage multiple symptoms, which can streamline treatment.

Q: What type of specialist typically prescribes or monitors treatment with Contus?

A: For its common use in the relief of cold and allergy symptoms, Contus is typically initiated and monitored by a General Practitioner, Family Doctor, or Pharmacist. The product is generally accessed through primary care.

Q: What patient information resources are officially recommended for Contus?

A: The primary recommended resource is the official Patient Information Leaflet (PIL) or Medication Guide that is packaged with the medicine. These documents are officially reviewed by regulatory bodies and contain essential information regarding the drug's approved use and safety profile.

Q: Does Contus interact with any common vaccines?

A: The official regulatory documents regarding drug interactions do not contain specific information about the interaction patterns between Contus and common vaccines.

Q: Is Contus available as an injectable form?

A: The official product documentation, which defines the drug's approved forms, only lists oral forms of Contus, including Tablets, Syrup, and Oral Liquid.

How should Contus be stored and disposed of?

How to Store and Dispose of Contus?

Official regulatory guidelines mandate specific storage and disposal requirements to maintain product integrity and ensure safety.

Storage Conditions

Contus must be stored at or below 30 C and protected from light and moisture by keeping it in its tightly closed original container. It is strictly required that the medicine must not be frozen. All formulations must be kept out of the sight and reach of children.


Disposal Instructions

Unused or expired Contus should be disposed of through an official drug take-back program where available. The medicine must not be disposed of in wastewater (e.g., flushed down the toilet). If no take-back program is accessible, the unused product should be mixed with an undesirable substance (such as dirt) and sealed in a container before being placed in household trash, as per general household disposal protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Contus found in:

A-Z Index: